Etoricoxib

Etoricoxib
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: C; Not recommended;
Routes of; administration	By mouth
ATC code	M01AH05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	100%
Protein binding	92%
Metabolism	Liver, CYP extensively involved (mainly CYP3A4)
Elimination half-life	22 hours
Excretion	Kidney (70%) and fecal (20%)
Identifiers
	IUPAC name 5-Chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine;
CAS Number	202409-33-4 ;
PubChem CID	123619;
IUPHAR/BPS	2896;
DrugBank	DB01628 ;
ChemSpider	110209 ;
UNII	WRX4NFY03R;
KEGG	D03710 ;
ChEBI	CHEBI:6339 ;
ChEMBL	ChEMBL416146 ;
CompTox Dashboard (EPA)	DTXSID3046457 ;
ECHA InfoCard	100.207.709
Chemical and physical data
Formula	C18H15ClN2O2S
Molar mass	358.84 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(c3ccc(c2cc(Cl)cnc2c1cnc(cc1)C)cc3)C;
	InChI InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3 ; Key:MNJVRJDLRVPLFE-UHFFFAOYSA-N ;
	(verify)

Etoricoxib, sold under the brand name Arcoxia, is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.

It was patented in 1996 and approved for medical use in 2002.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.